At the news
? BULLISHIMPACT 8/10 8-K filed Feb 26, 2026 at 07:19 ET
BioCryst reported a transformative 2025 with $601.8 million in ORLADEYO net revenue (up 38% YoY), achieving its first full-year profitability on record GAAP and non-GAAP operating profit. The company completed the acquisition of Astria Therapeutics, adding the late-stage HAE candidate navenibart, and maintained its 2026 revenue guidance of $625–$645 million.
- Full year 2025 ORLADEYO net revenue was $601.8 million, a 38% year-over-year increase (43% excluding European business sale)
- Achieved record GAAP operating profit of $341.0 million and non-GAAP operating profit of $214.2 million in 2025
- Completed acquisition of Astria Therapeutics in January 2026, adding navenibart, a Phase 3 monoclonal antibody for HAE prophylaxis
- Received FDA approval for ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access